Frameshift peptide neoantigen–Major Histocompatibility Complex (FSP-MHC) (FSP-MHC)

Frameshift peptide neoantigen–Major Histocompatibility Complex (FSP-MHC) refers to the presentation of novel peptides, generated by frameshift mutations, on the surface of tumor cells via MHC molecules. These mutations typically occur in tumors with microsatellite instability (MSI) or mismatch repair deficiency (dMMR), where the loss of DNA repair mechanisms leads to insertions or deletions in coding microsatellites. Because frameshift mutations result in entirely new amino acid sequences downstream of the mutation, FSPs are highly immunogenic and perceived as completely foreign by the immune system. This makes the FSP-MHC complex an ideal target for cancer immunotherapies, including neoantigen vaccines and TCR-engineered T-cell therapies. By specifically recognizing these complexes, the immune system can selectively eliminate malignant cells while sparing healthy tissue that lacks these specific genetic alterations.

Other names

Frameshift-derived neoantigen-HLA complexMSI-derived neoantigen-MHC complexFrameshift peptide-MHCFSP-HLA complex

Induction of CD8+ and CD4+ T-cell mediated cytotoxicity against tumor cells presenting frameshift-derived peptides on MHC molecules.